MALVERN, Pa.--(BUSINESS WIRE)--VenatoRx Pharmaceuticals today announced that its founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.
Now in its 33rd year, the program has expanded to recognize business leaders in more than 145 cities and more than 60 countries throughout the world. Widely considered one of the most prestigious business awards programs in the U.S., the award recognizes entrepreneurs and leaders of high-growth companies who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities, while also transforming our world.
“We are honored to receive the EY Entrepreneur Of The Year 2019 award and share this recognition with our esteemed colleagues who work tirelessly every day to realize our mission and vision to discover—and ultimately make clinically available—new medicines to treat multi-drug-resistant infections (‘superbugs’) and hard-to-treat viral infections,” said Drs. Burns, Pevear and Xerri. “We are proud that all of our investigational molecules are discovered internally. We have built a world-class, in-house, R&D organization that has filed over 100 patents spanning multiple research programs. We look forward to representing the Greater Philadelphia area health and life sciences community on a national stage and to sharing our story.”
Drs. Burns, Pevear and Xerri were selected as winners by a panel of independent judges. Regional award winners are eligible for consideration for the Entrepreneur Of The Year National competition. Award winners in several national categories, as well as the Entrepreneur Of The Year National Overall Award winner, will be announced at the Entrepreneur Of The Year National Awards gala in Palm Springs, California, on November 16, 2019. The awards are the culminating event of the Strategic Growth Forum®, the nation’s most prestigious gathering of high-growth, market-leading companies.
About Entrepreneur Of The Year®
Entrepreneur Of The Year®, founded by EY, is the world’s most prestigious business awards program for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities and more than 60 countries. www.ey.com/eoy
Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards are nationally sponsored by SAP America and the Ewing Marion Kauffman Foundation. In Greater Philadelphia, sponsors also include PNC Bank, Donnelley Financial Solutions, Murray Devine & Company, SolomonEdwards Group, Ballard Spahr LLP, Morgan, Lewis & Bockius LLP, Pepper Hamilton LLP and Simkiss & Block.
About EY
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities. EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information, please visit www.ey.com.
About VenatoRx Pharmaceuticals
VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections. Founded in 2010, VenatoRx has built a world-class in-house R&D organization that has filed over 100 patents spanning multiple research programs. VenatoRx has received significant funding awards from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), Wellcome Trust, CARB-X, and the Defense Threat Reduction Agency (DTRA) as well as private equity investments from Versant Ventures, Abingworth, and Foresite Capital.
